

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 6185)

ANNOUNCEMENT

**ACCEPTANCE BY THE SHANGHAI STOCK EXCHANGE OF
APPLICATION MATERIALS FOR THE PROPOSED ISSUE OF A SHARES**

This announcement is made by CanSino Biologics Inc. (the “**Company**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the Company’s announcement dated October 14, 2019, circular dated October 14, 2019 and supplemental circular dated November 14, 2019 containing, among other things, related matters of the proposed initial public issue of A Shares (the “**Proposed Issue of A Shares**”) and listing on the Sci-Tech Innovation Board of the Shanghai Stock Exchange (the “**Shanghai Stock Exchange**”).

The board (the “**Board**”) of directors (the “**Directors**”) is pleased to announce that the Company has submitted the application materials in respect of the Proposed Issue of A Shares, including the A Share prospectus (the “**A Share Prospectus**”), to the Shanghai Stock Exchange, and has received a letter of acceptance issued by the Shanghai Stock Exchange in respect of the Company’s application for the Proposed Issue of A Shares on January 22, 2020. The A Share Prospectus will be published on the website of the Review and Approval of the Issuance and Listing of Stock on the Science and Technology Innovation Board of the Shanghai Stock Exchange at (kcb.sse.com.cn), and will be published on the website of the Stock Exchange at (www.hkexnews.hk) and the website of the Company at (www.cansinotech.com) on the same date pursuant to Rule 13.10B of the Listing Rules.

As the Proposed Issue of A Shares is subject to certain conditions precedent, it may or may not be completed. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the H shares of the Company. Further announcement(s) regarding the details and developments of the Proposed Issue of A Shares will be made by the Company as and when appropriate. This announcement appears for information purposes only and does not constitute an invitation or an offer to acquire, purchase or subscribe for the securities of the Company.

By Order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, January 22, 2020

As at the date of this announcement, the Board of Directors comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU and Dr. Dongxu QIU as executive Directors, Mr. Qiang XU, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive Directors.